Cargando…

Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis

BACKGROUND: Acute coronary syndrome (ACS) is an important disease threatening human life and health. Many studies have shown that the loading dose of atorvastatin can significantly improve the prognosis of patients with ACS, and reduce the mortality. However, this conclusion is not consistent. Thus,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Ziliang, Lu, Haili, Su, Qiang, Guo, Wenqin, Dai, Weiran, Li, Hongqing, Yang, Huafeng, Li, Lang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322895/ https://www.ncbi.nlm.nih.gov/pubmed/28231287 http://dx.doi.org/10.1371/journal.pone.0171682

Ejemplares similares

The effect of alprostadil on preventing contrast-induced nephropathy for percutaneous coronary intervention in diabetic patients: A systematic review and meta-analysis
por: Ye, Ziliang, et al.
Publicado: (2016)

Clinical effect of trimetazidine on prevention of contrast-induced nephropathy in patients with renal insufficiency: An updated systematic review and meta-analysis
por: Ye, Ziliang, et al.
Publicado: (2017)

Effect of High Dose Rosuvastatin Loading before Percutaneous Coronary Intervention on Contrast-Induced Nephropathy
por: Yun, Kyeong Ho, et al.
Publicado: (2014)

Effect of preoperative loading dose ticagrelor and clopidogrel on no-reflow phenomenon during intervention in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis
por: Dai, Weiran, et al.
Publicado: (2018)

Baseline Serum Uric Acid Levels Are Associated with All-Cause Mortality in Acute Coronary Syndrome Patients after Percutaneous Coronary Intervention
por: Ye, Ziliang, et al.
Publicado: (2018)

Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction
por: Kim, Ji Won, et al.
Publicado: (2014)

Erratum to: Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction
por: Kim, Ji Won, et al.
Publicado: (2014)

Efficacy and safety of nicorandil on perioperative myocardial injury in patients undergoing elective percutaneous coronary intervention: results of the PENMIPCI trial
por: Ye, Ziliang, et al.
Publicado: (2018)

Reduced Left Ventricular Ejection Fraction Is a Risk Factor for In-Hospital Mortality in Patients after Percutaneous Coronary Intervention: A Hospital-Based Survey
por: Ye, Ziliang, et al.
Publicado: (2018)

Meta-analysis of the relationship between single nucleotide polymorphism of IL-10-1082G/A and rheumatic heart disease
por: Dai, Weiran, et al.
Publicado: (2018)

Short-versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials
por: Li, Hongqing, et al.
Publicado: (2018)

Efficacy of high-dose rosuvastatin preloading in patients undergoing percutaneous coronary intervention: a meta-analysis of fourteen randomized controlled trials
por: Pan, Yilong, et al.
Publicado: (2015)

Comparison of the Treatment Efficacy of Rosuvastatin versus Atorvastatin Loading Prior to Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction
por: Adel, Esraa M., et al.
Publicado: (2022)

The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome
por: Sexton, Travis R., et al.
Publicado: (2014)

Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India
por: Roy, Debabrata, et al.
Publicado: (2020)

Efficacy and safety of an antithrombotic regimen for atrial fibrillation patients with acute coronary syndrome or those undergoing percutaneous coronary intervention: a meta-analysis
por: Guo, Wenqin, et al.
Publicado: (2020)

Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis
por: Long, Manyun, et al.
Publicado: (2020)

Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention
por: Yang, Jing, et al.
Publicado: (2015)

Comparison of lower loading dose of prasugrel with conventional loading dose of prasugrel in Indian patients undergoing percutaneous coronary interventions
por: Kumari, Priti, et al.
Publicado: (2018)

Rosuvastatin Reduces Blood Viscosity in Patients with Acute Coronary Syndrome
por: Jung, Lae-Young, et al.
Publicado: (2016)

Comparison between rosuvastatin and atorvastatin for the prevention of contrast-induced nephropathy in patients with STEMI undergoing primary percutaneous coronary intervention
por: Firouzi, Ata, et al.
Publicado: (2018)

Effects of High- or Moderate-intensity Rosuvastatin on 1-year Major Adverse Cardiovascular Events Post-percutaneous Coronary Intervention
por: Chehrevar, Morteza, et al.
Publicado: (2022)

Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
por: Liu, Yong, et al.
Publicado: (2014)

Pharmacology before, during and after percutaneous coronary intervention
por: Zaman, Azfar G, et al.
Publicado: (2021)

Circulating miRNA-155 as a Potential Biomarker for Coronary Slow Flow
por: Su, Qiang, et al.
Publicado: (2018)

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Markers in Acute Coronary Syndrome
por: Umrani, Salman, et al.
Publicado: (2020)

Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients at Cardiovascular Risk
por: Yang, Yujin, et al.
Publicado: (2021)

Role of depression in secondary prevention of Chinese coronary heart disease patients receiving percutaneous coronary intervention
por: Feng, Can, et al.
Publicado: (2017)

Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
por: Khurana, Sushant, et al.
Publicado: (2015)

Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome
por: Al-kuraishy, Hayder M., et al.
Publicado: (2018)

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients with Acute Coronary Syndrome
por: Kumar, Besham, et al.
Publicado: (2019)

Effect of loading dose of atorvastatin therapy prior to percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of six randomized controlled trials
por: Ma, Mingfeng, et al.
Publicado: (2019)

Lipid Biomarkers in Acute Myocardial Infarction Before and After Percutaneous Coronary Intervention by Lipidomics Analysis
por: Feng, Limin, et al.
Publicado: (2018)

Coronary Circulatory Indexes Before and After Percutaneous Coronary Intervention in a Porcine Tandem Stenoses Model
por: Chang, Haseong, et al.
Publicado: (2021)

Anti-inflammatory effects of rosuvastatin treatment on coronary artery ectasia patients of different age groups
por: Fan, Cheng-Hui, et al.
Publicado: (2020)

Effects of Percutaneous Coronary Intervention on Serum Angiopoietin-2 in Patients with Coronary Heart Disease
por: Zeng, Zhi-Yu, et al.
Publicado: (2016)

Should Aortic Valve Calcification be Checked Before Percutaneous Coronary Intervention?
por: Kaji, Shuichiro
Publicado: (2017)

Effect of Alirocumab and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaque in Coronary Artery Disease Seen on Near-Infrared Spectroscopy Intravascular Ultrasound (ANTARES)
por: Otake, Hiromasa, et al.
Publicado: (2019)

A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Li, Yachao, et al.
Publicado: (2023)

Effects of atorvastatin and rosuvastatin on dysfunctional coronary circulation in patients with ST-segment elevation myocardial infarction
por: Zhou, Langping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g0a12c0l449ivqu5qrn1bur7i3